← Leaderboards
Kenneth Wayne Narducy
St. Charles Pharmaceuticals
$1,061,192
Attributed
$1,061,192
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $556.6K · FY2007–10$1M$750K$500K$250K$0
'07
'08
'09
'10
Funding mix
By agency
NIH$1,061,192 · 1
By mechanism
U44$1,061,192 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Charles Pharmaceuticals
Same institution · by research overlap
- Anthony L Vaccarino$562,081
- Kenneth W Narducy$2,281,698
Others in their field
Top investigators on “Collaborations”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$557,285,233
- David Heimbrook · Leidos Biomedical Research, Inc.$519,426,565
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$479,076,140
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Albert Lazzarini · California Institute Of Technology$382,990,355
Research focus
CollaborationsControlled Clinical TrialsCodeineAffectClinical ResearchAllodyniaAcetaminophenClinical TrialsAnalgesicsAnalogAcuteAnimalsAnticonvulsantsAntidepressive AgentsAmericanAdverse EffectsAmitriptylineBaseCarboxylic AcidsChronicChronic Constriction InjuryChung ModelAnimal ModelCountry
Grant awards (5)
Preclinical Development of SCP-123 for Neuropathic Pain$1
U44 · FY2010 · NS · contact PI
Preclinical Development of SCP-123 for Neuropathic Pain$1
U44 · FY2009 · NS · contact PI
Preclinical Development of SCP-123 for Neuropathic Pain$454,566
U44 · FY2008 · NS · contact PI
Preclinical Development of SCP-123 for Neuropathic Pain$49,988
U44 · FY2008 · NS · contact PI
Preclinical Development of SCP-123 for Neuropathic Pain$556,636
U44 · FY2007 · NS · contact PI